The effect of addition of low dose abiraterone to the ADT+RT in local recurrent prostate cancers

The effect of addition of low dose abiraterone to the ADT+RT in local recurrent prostate cancers after previous surgery, in terms of biochemical recurrence

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120618010057N2

Enrollment

Registered

2022-04-25

Start date

2022-04-25

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer. Malignant neoplasm of prostate

Interventions

Intervention 1: Hormone therapy and radiotherapy plus abiraterone. Androgen deprivation therapy (ADT) and radiotherapy + abiraterone 250mg daily + prednisolone 5mg daily until one year later. Abirater

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Prostate cancer patients with local recurrence after radical prostatectomy

Exclusion criteria

Exclusion criteria: Hormone resistant

Design outcomes

Primary

Measure	Time frame
Biochemical free survival. Timepoint: 3 months interval. Method of measurement: Prostate-Specific Antigen (PSA) test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbolfazl Razzaghdoust

Shahid Beheshti University of Medical Sciences

razzaghdoust@sbmu.ac.ir+98 21 2256 7222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026